tbjournalТуберкулез и социально значимые заболеванияTuberculosis and socially significant diseases2413-03462413-0354ООО «Ин-Трендtbjournal-265Research ArticleОБЗОР ЛИТЕРАТУРЫLITERATURE REVIEWПроблемы формирования устойчивости микобактерий туберкулеза к лекарствам и возможности респираторного фторхинолона спарфлоксацинаThe problems of formations of drug resistance M.tuberculosis and the possibilities of the respiratory fluoroquinolones SparfloxacinКареваЕ. Н.KarevaE. N.

Карева Елена Николаевна – профессор кафедры молекулярной фармакологии ГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, доктор медицинских наук, профессор

119121, г. Москва, ул. Б. Пироговская, д. 9аТел.: + 7 (499) 264-60-05, + 7 (968) 546-22-80

elenakareva@mail.ruБогородскаяЕ. М.BogorodskayaE. M.

Богородская Елена Михайловна – директор ГКУЗ города Москвы «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения г. Москвы», доктор медицинских наук

107014, Москва, ул. Стромынка, д. 10Тел.: + 7 (499) 268-00-05

mnpcbtdir2012@yandex.ruГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииRussian FederationГКУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»Russian Federation201527012025016774Copyright © Карева Е.Н., Богородская Е.М., 20252025Карева Е.Н., Богородская Е.М.Kareva E.N., Bogorodskaya E.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tb-journal.ru/jour/article/view/265

В обзоре приведены современные сведения о механизмах развития резистентности микобактерий туберкулеза к антибактериальным препаратам. Представлены сведения о молекулярных механизмах действия, основных фармакокинетических характеристиках и побочных эффектах спарфлоксацина. Обсуждается вопрос применения спарфлоксацина в терапии туберкулеза легких с множественной лекарственной устойчивостью возбудителя.

In this review you can find data about tuberculosis mycobacterium resistance mechanisms to antibiotics. The data include molecular action mechanism, main pharmacokinetic characteristics and side effects of Sparfloxacin. The question of Sparfloxacin application in MDR-TB treatment is discussed in this article.

спарфлоксацинлекарственная устойчивость микобактерии туберкулезамеханизмы действияфармакокинетикаsparfloxacindrug resistance of M.tuberculosismechanisms of actionpharmacokinetics.ReferencesЛазарева Н.Б., Хайменова Т.Ю., Хайменов А.Я. Роль респираторных фторхинолонов в лечении туберкулеза лeгких при неэффективности препаратов первой линии // Антибиотики и химиотерапия. – 2008. – № 53 (5/6). – С. 14-20.Лазарева Н.Б., Хайменова Т.Ю., Хайменов А.Я. Роль респираторных фторхинолонов в лечении туберкулеза лeгких при неэффективности препаратов первой линии // Антибиотики и химиотерапия. – 2008. – № 53 (5/6). – С. 14-20.Падейская Е.Н. Спарфлоксацин - антибактериальный препарат широкого спектра действия // Рус. мед. журн. – 2002. – № 10 (3). – (Инфекции. Иммунология. Аллергология).Падейская Е.Н. Спарфлоксацин - антибактериальный препарат широкого спектра действия // Рус. мед. журн. – 2002. – № 10 (3). – (Инфекции. Иммунология. Аллергология).Соколова Г.Б., Хайменова Т.Ю., Лазарева Я.В., Хайменов А.Я. Спарфлоксацин в комплексной терапии туберкулeза лeгких// Антибиотики и химиотерапия. – 2008. – № 53 (5/6). – С. 21-27.Соколова Г.Б., Хайменова Т.Ю., Лазарева Я.В., Хайменов А.Я. Спарфлоксацин в комплексной терапии туберкулeза лeгких// Антибиотики и химиотерапия. – 2008. – № 53 (5/6). – С. 21-27.Степашин Ю.Г., Степашина В.Н., Шемякин И.Г. Молекулярные механизмы устойчивости микобактерии туберкулеза к лекарственным препаратам // Антибиотики и химиотерапия. – 1999. – № 4. – С. 39-43.Степашин Ю.Г., Степашина В.Н., Шемякин И.Г. Молекулярные механизмы устойчивости микобактерии туберкулеза к лекарственным препаратам // Антибиотики и химиотерапия. – 1999. – № 4. – С. 39-43.Aubry A., Pan X.S., Fisher L.M. et al. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity //Antimicrob. Agents Chemother. – 2004. – Vol. 48. – N. 4. – P. 1281-1288.Aubry A., Pan X.S., Fisher L.M. et al. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity //Antimicrob. Agents Chemother. – 2004. – Vol. 48. – N. 4. – P. 1281-1288.Balganesh T.S., Alzari P.M., Cole S.T. Rising standards for tuberculosis drug development // Trends in Pharmacol. Sci. – 2008. – Vol. 29. – N. 11. – P. 576-581.Balganesh T.S., Alzari P.M., Cole S.T. Rising standards for tuberculosis drug development // Trends in Pharmacol. Sci. – 2008. – Vol. 29. – N. 11. – P. 576-581.Bolhuis M.S., Panday P.N., Pranger A.D. et al. Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and beta-lactams // Pharmaceutics. – 2011. – Vol. 3. – P. 865-913.Bolhuis M.S., Panday P.N., Pranger A.D. et al. Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and beta-lactams // Pharmaceutics. – 2011. – Vol. 3. – P. 865-913.Dwyer D.J., Kohanski M.A., Hayete B., Collins J.J. Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli // Mol. Syst. Biol. – 2007. – Vol. 3. – P. 91. Published online 2007 March 13. doi: 10.1038/msb4100135.Dwyer D.J., Kohanski M.A., Hayete B., Collins J.J. Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli // Mol. Syst. Biol. – 2007. – Vol. 3. – P. 91. Published online 2007 March 13. doi: 10.1038/msb4100135.Global overview of new anti-TB compounds / Proceedings of the 17th Eur. Congr. of Clin. Microbiol. Infect. Dis. and 25th Int. Congr. of Chemotherapy. – 2007.Global overview of new anti-TB compounds / Proceedings of the 17th Eur. Congr. of Clin. Microbiol. Infect. Dis. and 25th Int. Congr. of Chemotherapy. – 2007.http://genolist.pasteur.fr/TubercuListhttp://genolist.pasteur.fr/TubercuListhttp://www.who.int/tdr/http://www.who.int/tdr/Huang C.S., Wu C.C. Observation of the clinical efficacy of sparfloxacin in the treatment of multiple drug resistance pneumonial tuberculosis // Chinese J. Antibiotics. – 2000. – Vol. 25. – N. 4. – P. 302–303.Huang C.S., Wu C.C. Observation of the clinical efficacy of sparfloxacin in the treatment of multiple drug resistance pneumonial tuberculosis // Chinese J. Antibiotics. – 2000. – Vol. 25. – N. 4. – P. 302–303.Ji Y.M., Dong L.H., Wang Q., Yu W.Q. Short-term observation of curative effects in treatment of multiple-drug resistance pulmonary tuberculosis with sparfloxacin and ofloxacin // J. Postgrad. Med. – 2001. – Vol. 24. – N. 7. – P. 32–33.Ji Y.M., Dong L.H., Wang Q., Yu W.Q. Short-term observation of curative effects in treatment of multiple-drug resistance pulmonary tuberculosis with sparfloxacin and ofloxacin // J. Postgrad. Med. – 2001. – Vol. 24. – N. 7. – P. 32–33.Kawahara S., Tada A., Nagare H. Clinical evaluation of new quinolones as antituberculosis drugs // Kekkaku. – 1999. – Vol. 74. – N. 1. – P. 71-75.Kawahara S., Tada A., Nagare H. Clinical evaluation of new quinolones as antituberculosis drugs // Kekkaku. – 1999. – Vol. 74. – N. 1. – P. 71-75.Lalande V., Truffot-Pernot C.H., Paccaly-Moulin A., Grosset J. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice // Antimicrob. agents and chemother. – 1993. – Vol. 37. – N. 3. – P. 407-413.Lalande V., Truffot-Pernot C.H., Paccaly-Moulin A., Grosset J. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice // Antimicrob. agents and chemother. – 1993. – Vol. 37. – N. 3. – P. 407-413.Lenaerts A.J., De Groote M.A., Orme I.M. Preclinical testing of new drugs for tuberculosis: current challenges // Trends in Microbiology. – 2008. – Vol. 16. – N. 2. – P. 48-54.Lenaerts A.J., De Groote M.A., Orme I.M. Preclinical testing of new drugs for tuberculosis: current challenges // Trends in Microbiology. – 2008. – Vol. 16. – N. 2. – P. 48-54.Lubasch A., Erbes R., Mauch H., Lode H. Sparfoxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy // Eur. Resp. J. – 2001. - Vol. 17. – P. 641-646.Lubasch A., Erbes R., Mauch H., Lode H. Sparfoxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy // Eur. Resp. J. – 2001. - Vol. 17. – P. 641-646.Mitchison D., Davies G. The chemotherapy of tuberculosis: past, present and future // Int. J. Tuberc. Lung Dis. – 2012. – Vol. 16. – N. 6. – P. 724-732.Mitchison D., Davies G. The chemotherapy of tuberculosis: past, present and future // Int. J. Tuberc. Lung Dis. – 2012. – Vol. 16. – N. 6. – P. 724-732.Pranger A.D., Alffenaar J.W.C., Aarnoutse R.E. Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach // Current Pharmaceutical Design. – 2011. – Vol. 17. – N. 27. – P. 2900-2930.Pranger A.D., Alffenaar J.W.C., Aarnoutse R.E. Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach // Current Pharmaceutical Design. – 2011. – Vol. 17. – N. 27. – P. 2900-2930.Shandil R.K., Jayaram R., Kaur P. et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy // Antimicrob. Agents Chemother. – 2007. – Vol. 51. – N. 2. – P. 576–582.Shandil R.K., Jayaram R., Kaur P. et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy // Antimicrob. Agents Chemother. – 2007. – Vol. 51. – N. 2. – P. 576–582.Singh M., Chauhan D.S., Gupta P. et al. In vitro effect of fluoroquinolones against Mycobacterium tuberculosis isolates from Agra & Kanpur region of north India // Indian J. Med. Res. – 2009. – Vol. 129. – P. 542-547.Singh M., Chauhan D.S., Gupta P. et al. In vitro effect of fluoroquinolones against Mycobacterium tuberculosis isolates from Agra & Kanpur region of north India // Indian J. Med. Res. – 2009. – Vol. 129. – P. 542-547.Singla R., Gupta S., Gupta R., Arora V.K. Efficacy and safety of sparfloxacin in combination with kanamycin and ethionamide in multidrug-resistant pulmonary tuberculosis patients: preliminary results // Int. J. Tuberc. Lung Dis. – 2001. – Vol. 5, N. 6. – P. 559-563.Singla R., Gupta S., Gupta R., Arora V.K. Efficacy and safety of sparfloxacin in combination with kanamycin and ethionamide in multidrug-resistant pulmonary tuberculosis patients: preliminary results // Int. J. Tuberc. Lung Dis. – 2001. – Vol. 5, N. 6. – P. 559-563.Struwe M., Greulich K.O., Perentes E. et al. // J. Invest. Dermatol. – 2009. – Vol. 129. – N. 3. – P. 699-704.Struwe M., Greulich K.O., Perentes E. et al. // J. Invest. Dermatol. – 2009. – Vol. 129. – N. 3. – P. 699-704.Sukhesh R.A.O. Uncontrolled trial of sparfloxacin in retreatment of pulmonary tuberculosis // Respirology. – 2004. – Vol. 9. – N. 3. – P. 402–405.Sukhesh R.A.O. Uncontrolled trial of sparfloxacin in retreatment of pulmonary tuberculosis // Respirology. – 2004. – Vol. 9. – N. 3. – P. 402–405.Sun W., Wenyi C., Cunzhi L. et al. A randomized controlled study of sparfloxacin and ofloxacin in the treatment of multiple drug resistant pulmonary tuberculosis // Chinese J. Antibiotics. – 2000. – Vol. 25. – N. 1. – P. 52–54.Sun W., Wenyi C., Cunzhi L. et al. A randomized controlled study of sparfloxacin and ofloxacin in the treatment of multiple drug resistant pulmonary tuberculosis // Chinese J. Antibiotics. – 2000. – Vol. 25. – N. 1. – P. 52–54.Wade M.M., Zhang Y. Mechanisms of drug resistance in Mycobacterium tuberculosis // Front. Biosci.- 2004. – Vol. 9. – P. 975–994.Wade M.M., Zhang Y. Mechanisms of drug resistance in Mycobacterium tuberculosis // Front. Biosci.- 2004. – Vol. 9. – P. 975–994.Wei S., Wenyi C., Cunzhi L.et al. A randomized controlled study of sparfloxacin and ofloxacin in the treatment of multiple drug resistant pulmonary tuberculosis // Chinese J. Antibiotics. – 2000. – Vol. 25. – N. 1. – P. 53–55.Wei S., Wenyi C., Cunzhi L.et al. A randomized controlled study of sparfloxacin and ofloxacin in the treatment of multiple drug resistant pulmonary tuberculosis // Chinese J. Antibiotics. – 2000. – Vol. 25. – N. 1. – P. 53–55.Zhang Z., Lu J., Wang Y. et al. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China // Antimicrob. Agents Chemother. – 2014. – Vol. 58. – N. 1. – P. 364-369.Zhang Z., Lu J., Wang Y. et al. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China // Antimicrob. Agents Chemother. – 2014. – Vol. 58. – N. 1. – P. 364-369.Ziganshina L.E., Squire S.B. Fluoroquinolones for treating tuberculosis: review // The Cochrane Library. – 2009. – Issue 1. – http://www.thecochranelibrary.comZiganshina L.E., Squire S.B. Fluoroquinolones for treating tuberculosis: review // The Cochrane Library. – 2009. – Issue 1. – http://www.thecochranelibrary.com

The authors declare that there are no conflicts of interest present.